Stem Cell Therapy Shows Promise for Preventing Heart Failure After Heart Attacks
Large trial tests umbilical cord stem cells to prevent heart failure in heart attack patients with reduced heart function.
20 articles
Large trial tests umbilical cord stem cells to prevent heart failure in heart attack patients with reduced heart function.
Clinical trial tested whether bone marrow stem cells could improve heart function beyond standard bypass surgery alone.
Small trial tests safety of injecting patients' own cardiac stem cells to regrow dead heart tissue and restore function.
Researchers tested a novel stem cell therapy using umbilical cord cells on a pericardial matrix to repair heart tissue after heart attacks.
Researchers tested injecting cardiac stem cells directly into heart arteries after heart attacks to promote healing and regeneration.
Researchers tested whether stem cells from healthy hearts could help repair damage in heart attack patients, offering hope for cardiac regeneration.
115-patient trial tested CardioCell stem cell treatment against placebo for chronic heart failure patients with promising regenerative approach.
Completed study tested regenerative cardiac therapy in 105 heart attack patients, comparing stem cell treatment to placebo controls.
CAR-M2 therapy successfully reversed kidney scarring in lab studies by eliminating harmful endothelial cells and promoting healing.
Novel liposome therapy delivers miR-10a to atherosclerotic plaques, reprogramming inflammatory macrophages and reducing disease progression in mice.
Researchers created the first comprehensive atlas of bone metastases, revealing new immune therapy combinations that could help patients.
Scientists discover how damaged heart cells transform into new blood vessels, potentially revolutionizing heart failure treatment.
A new review examines how drugs that clear senescent cells could transform treatment of age-related cardiovascular disease.
A 330-patient multicenter RCT tests whether thymosin ฮฑ1 can curb immune dysregulation and organ dysfunction after acute type A aortic dissection repair.
A 2025 review maps the molecular drivers of cardiac aging and evaluates drugs, CRISPR, stem cells, and lifestyle as countermeasures.
Breakthrough study shows one epigenetic factor can transform cardiac fibroblasts into heart muscle cells, improving function after myocardial infarction.
Researchers created synthetic immune receptors that boost macrophages' ability to clear cellular debris, reducing inflammation in liver and heart disease.
Scientists discover how to enhance cancer immunotherapy by converting tumor-supporting immune cells into tumor-fighting ones.
The first disease-specific treatment for Barth syndrome gains FDA accelerated approval, targeting mitochondrial dysfunction to restore muscle strength.
A landmark Phase 3 trial evaluates whether omecamtiv mecarbil, a cardiac myosin activator, reduces cardiovascular death in HFrEF patients.